Tumor lenvatinib addiction and withdrawal rebound response in patients with advanced endometrial cancer

Combination therapy of lenvatinib, a multitargeted tyrosine kinase inhibitor (TKI), plus pembrolizumab, a monoclonal antibody targeting programmed death receptor 1 (PD-1), was recently approved by the Food and Drug Administration for therapy of advanced endometrial cancer. This case series highlight...

詳細記述

保存先:
書誌詳細
主要な著者: Clarissa Lam (著者), Debra Sarasohn (著者), Britta Weigelt (著者), Dmitriy Zamarin (著者)
フォーマット: 図書
出版事項: Elsevier, 2023-10-01T00:00:00Z.
主題:
オンライン・アクセス:Connect to this object online.
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

インターネット

Connect to this object online.

3rd Floor Main Library

予約・返却請求 3rd Floor Main Library
請求記号: A1234.567
所蔵 1 利用可